Optimal management of digital ulcers in systemic sclerosis
- PMID: 26109864
- PMCID: PMC4474386
- DOI: 10.2147/TCRM.S82561
Optimal management of digital ulcers in systemic sclerosis
Abstract
Raynaud's phenomenon and digital ulcerations are two common clinical features seen in patients with systemic sclerosis. They are painful and lead to significant morbidity and altered hand function within this patient population. While currently there are no US Food and Drug Administration (FDA)-approved medications for the treatment of digital ulcerations in the United States, clinical trials have supported the use of pharmacologic and nonpharmacologic modalities in facilitating healing of existing digital ulcers and preventing formation of new ulcers. This article reviews the published data on these therapeutic options.
Keywords: Raynaud’s phenomenon; digital ulcers; scleroderma; systemic sclerosis; treatment.
References
-
- Denton CP, Korn JH. Digital ulceration and critical digital ischaemia in scleroderma. Scleroderma Care Res. 2003;1:12–16.
-
- Baron M. Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. Clin Rheumatol. 2014;33(2):207–214. - PubMed
-
- Sunderkotter C, Hergott I, Bruckner C, et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol. 2009;160:835–843. - PubMed
-
- Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: a single-center retrospective longitudinal study. J Rheumatol. 2007;34:2423–2430. - PubMed
-
- Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology. 2009;48:19–24. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
